Teva Generic medical industry from Israel. Recently this company passed a resolution in their board of directors meeting, to purchase US based another generic
medical industry, that is Mylan.
These companies are top two companies of world
in generic medical field.
Teva
wanted to close this deal $82 for share.
Offer value is Rs.2,50,000 Cr ($,000 Cr Dollars)
As per Teva chairmen Peter burg Teva board of directors passed a resolution unanimously.
But Mylan not responded.
It’s a Big Deal :
If Teva
purchase mylan, it’s an a big deal in pharma industry. This two companies yearly
earning is $ 3,000 Cr in Rs.1,80,000 Cr. If Teva deal completes with Mylan,
Teva Reach first place world wide in generic medicine industry. At right now US based mylan is in second place
in world wide.
Ranbaxy
reached world's 5th place after Sun pharma merge with Ranbaxy. TEVA
and Mylan facing big competitions from developing companies like Ranbaxy. Teva
feels that if the deal complete with Mylan, then facing competitions are easy. Mylan started their activity in India in 2012
under the supervision of Rajiv malik president and Executive director of
Mylan. Rajiv Malik is Indian descent.
About TEVA :
Established : 1901
Place : Peta Tikwa, Israil
Net
profit : $ 2,030 Cr
Shares
Listed : New york Stock Exchange, Tel Aviv Stock Exchange
Working
Are : Israil, South America, North
America, Iropa
Placed
at world’s first place under generic Medicine Companies
About Mylan :
Established : 1961
Place : Pensilinia, USA
Net
Profit : $ 770 Cr
Shares
Listed : Nasdac
Working
Are : North America, Iropa, Asia
Pacipic, Africa and middle east
Placed
at world’s Second place under generic Medicine Companies
NATCO crushing :
If this
deal completes NATCO pharma may face some patent problems on ‘COPAXONE MEDICINE.
With this issue only Natco pharma stock price was gone up to 6% below in 22nd April 2015 trading. At end of the session natco phrma stock
price closed with 4% loss at Rs. 2,064/-
‘COPAXONE’
medicene have full demand world wide which is using in nerve related diseases treatment. In 2014 COPAXONE sales value
is Rs.26,460 Cr. TEVA get 50% profit with copaxone sales in total TEVA’s profit.
With this figures we can understand what is the role of COPAXONE in TEVA Pharma. COPAXONE patent rights are ending 2015 September, Which patent rights have TEVA.
Natco
along with Mylan got a world wide permission for generic version of
COPAXONE. TEVA reached some courts. Some
courts given judgement in the favor of NATCO. But one case is still pending in
USA courts. NATCO got a permission for this product sales in USA through USFDA.
If TEVA
completes the deal with mylan. Here one question is raising what will happened in
the deal of NATCO and MYLAN on the marketing of COPAXONE.
